Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 28, 2016
FDA Grants Tazemetostat Fast Track Designation for DLBCL with EZH2 Activating Mutations Company Focuses Phase 2 Solid Tumor Study on INI1-Negative Tumors and Expands Epithelioid Sarcoma Cohort CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigeneti...
Nov 21, 2016
CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert A. Copeland, Ph.D., has been named a fellow of the American Association for the Advancement of Science (AAA...
Nov 3, 2016
Robust Clinical Program Underway for Tazemetostat in Multiple Cancer Indications and Treatment Settings as Both Monotherapy and Combination Agent Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating nove...
Oct 31, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that it has entered into two Cooperative Research and Development Agreements (CRADAs) with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (N...
Oct 27, 2016
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and audio webcast on Thursday, November 3, 2016, at 8:30 a.m. Eastern Time to report recent company highlights and third quarte...
Sep 29, 2016
CAMBRIDGE, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the position of vice president of regulatory affairs and quality assurance. Strode will report to Epizyme's ...
Sep 21, 2016
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement with Foundation Medicine, Inc. to support patient identification and enrollment for Epizyme's ongoing Phase...
Sep 15, 2016
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK's initiation of patient dosing in a Phase 1 clinical trial o...
Sep 1, 2016
CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at three investor conferences in September: Citi's 11th Annual Biotech Conference on Thursday, September 8 at 8:00 a.m. ET in Boston;Ro...
Aug 11, 2016
CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first patient has been dosed in the Company's global phase 2 study evaluating tazemetostat, a first-in-class EZH2 inhibitor, for the treatment of adults with meso...
Aug 8, 2016
Company Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018 Conference Call to Be Held Today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported financial results ...
Aug 1, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that management will host a conference call and audio webcast on Monday, August 8, 2016, at 8:30 a.m. Eastern Time to report business highlights and progress against the c...
Jun 22, 2016
Clinical trial to evaluate Epizyme's clinical-stage EZH2 inhibitor in combination with anti-PD-L1 cancer immunotherapy CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people w...
Jun 19, 2016
Tazemetostat demonstrates favorable safety profile consistent with prior clinical experience Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses observed in all patient cohorts CAMBRIDGE, Mass.--(BUSINESS WIRE...
May 12, 2016
CAMBRIDGE--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that data from four abstracts from the Company's clinical development program in support of tazemetostat for use in non-Hodgkin ...
= add release to Briefcase